The trillions of bacteria that reside in our intestines play important roles in our health. In addition to digestion, they also influence whether or not someone develops cancer—specifically, colorectal cancer—as well as how a patient responds to treatment. However, the specific pathways through which bacteria mediate these effects remain poorly defined.
Previously, Dr. Sonnenberg’s team identified a family of immune cells—known as innate lymphoid cells, or ILCs—that appear to be essential for normal interactions between our own cells and these bacteria, and now they’re seeking to characterize their effects more precisely. Specifically, the Sonnenberg Lab is interrogating the functional significance of ILCs in context of colorectal cancer, using both basic mouse models and translational patient-based studies.
Ultimately, Sonnenberg aims to uncover new insights and identify new targets that could be manipulated to enhance the effectiveness of existing immunotherapies as well as aid the development of novel immunotherapies for patients.
Projects and Grants
Modulating host-microbiota interactions to improve cancer immunotherapies
Weill Cornell Medicine | All Cancers | 2018
Let's spread the word about Immunotherapy! Click to share this page with your community.